Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Yaa-Hui Dong"'
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-13 (2023)
Abstract Background Use of combinations of long-acting β2 agonists/long-acting muscarinic antagonists (LABA/LAMA) in patients with chronic obstructive pulmonary disease (COPD) is increasing. Nevertheless, existing evidence on cardiovascular risk ass
Externí odkaz:
https://doaj.org/article/cfe257de5bbc44bc881e9e82b737f9f0
Autor:
Tanavij Pannoi, Chissanupong Promchai, Penjamaporn Apiromruck, Suwikran Wongpraphairot, Yaa-Hui Dong, Chen-Chang Yang, Wen-Chi Pan
Publikováno v:
PeerJ, Vol 12, p e16892 (2024)
Background Proton-pump inhibitors (PPIs) are prescribed to treat gastric acid-related diseases, while they may also have potential risks to population health. Recent studies suggested that a potential mechanism explaining the association between PPIs
Externí odkaz:
https://doaj.org/article/2726bf36b8b8447e9035921eb06a6f56
Autor:
Ju-Chieh Wung, Chia-Chen Hsu, Chi-En Wang, Yaa-Hui Dong, Chia-Chieh Lin, Szu-Yu Wang, Shih-Lin Chang, Yuh-Lih Chang
Publikováno v:
Advances in Pharmacological and Pharmaceutical Sciences, Vol 2024 (2024)
Introduction. Pharmacokinetic studies have shown that rifampin reduces the levels of oral anticoagulants during the initiation of coadministration, raising concerns about an increased thrombotic risk, but there are limited comparative clinical outcom
Externí odkaz:
https://doaj.org/article/494e333b61d2433dbfe2582fd6504d39
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Both sodium glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular protective effects in patients with type 2 diabetes mellitus. However, the comparative risk of GLP-1RA ve
Externí odkaz:
https://doaj.org/article/ba9e2ec19cc54c338b2aee2fa3ff3865
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 6 (2022)
Background To investigate the effectiveness and safety of withholding or restarting antithrombotic agents, and different antithrombotic therapies among patients with atrial fibrillation post‐intracranial hemorrhage. Methods and Results This is a na
Externí odkaz:
https://doaj.org/article/7b905db0396d4b3d9be3e4bca0defb51
Publikováno v:
Drugs - Real World Outcomes, Vol 6, Iss 3, Pp 93-104 (2019)
Abstract Introduction The new user cohort design is widely used to assess the effects of a new drug, such as dabigatran, but inherently excludes some users due to prior use of the comparator drug, for example warfarin. The prevalent new-user design o
Externí odkaz:
https://doaj.org/article/a99171e8df6847dcb70c446a714cbe6f
Publikováno v:
PLoS Medicine, Vol 16, Iss 9, p e1002894 (2019)
BackgroundInfection is a major complication in liver cirrhosis and causes major morbidity and mortality. However, the incidence and mortality related to these conditions in patients infected with hepatitis C virus (HCV) are unclear, as is whether ant
Externí odkaz:
https://doaj.org/article/2e31167ecd5e4e10a7ce28663a87600b
Publikováno v:
Journal of the Formosan Medical Association, Vol 115, Iss 9, Pp 744-751 (2016)
Ifosfamide, a widely used chemotherapeutic agent, has been frequently associated with encephalopathy. A larger-scale study was conducted to identify risk factors of ifosfamide-related encephalopathy, including hepatic function. Methods: Adult patient
Externí odkaz:
https://doaj.org/article/a9c6b352749f4d34bc376e2e0bcb40dc
Autor:
Yaa-Hui Dong, Jou-Wei Lin, Li-Chiu Wu, Chung-Yu Chen, Chia-Hsuin Chang, Kuan-Yu Chen, Mei-Shu Lai
Publikováno v:
Journal of the Formosan Medical Association, Vol 113, Iss 12, Pp 940-948 (2014)
The relationship between statin use and lung cancer remains unclear. Patients with diabetes mellitus, who are at higher risks for both cancer and atherosclerosis, are usually indicated for statin use. The objective was to explore the relationship bet
Externí odkaz:
https://doaj.org/article/c3e8d42e8d674c3ab35e8321d45e92c6
Autor:
Yaa-Hui Dong, 東雅惠
101
Background. There has been enormous growth in the use of secondary and tertiary data in pharmacoepidemiologic studies and health services research. In claims-based studies using secondary data from health insurance claims databases, comorbid
Background. There has been enormous growth in the use of secondary and tertiary data in pharmacoepidemiologic studies and health services research. In claims-based studies using secondary data from health insurance claims databases, comorbid
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/94773868930558648902
